ABT ABBOTT LABORATORIES

NYSE abbott.com


$ 129.00 $ -3.82 (-2.87 %)    

Wednesday, 15-Oct-2025 19:55:40 EDT
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 129.45
$ 128.00
$ 127.00 x 50
$ 129.66 x 50
$ 125.74 - $ 131.48
$ 109.21 - $ 139.33
14,906,379
na
225.3B
$ 0.58
$ 16.12
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-30-2025 06-30-2025 10-Q
2 04-30-2025 03-31-2025 10-Q
3 02-21-2025 12-31-2024 10-K
4 10-31-2024 09-30-2024 10-Q
5 07-31-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-16-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-17-2023 12-31-2022 10-K
12 11-01-2022 09-30-2022 10-Q
13 08-02-2022 06-30-2022 10-Q
14 05-03-2022 03-31-2022 10-Q
15 02-18-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-19-2021 12-31-2020 10-K
20 11-04-2020 09-30-2020 10-Q
21 07-29-2020 06-30-2020 10-Q
22 04-29-2020 03-31-2020 10-Q
23 02-21-2020 12-31-2019 10-K
24 10-31-2019 09-30-2019 10-Q
25 07-31-2019 06-30-2019 10-Q
26 05-01-2019 03-31-2019 10-Q
27 02-22-2019 12-31-2018 10-K
28 10-31-2018 09-30-2018 10-Q
29 08-01-2018 06-30-2018 10-Q
30 05-02-2018 03-31-2018 10-Q
31 02-16-2018 12-31-2017 10-K
32 11-02-2017 09-30-2017 10-Q
33 08-02-2017 06-30-2017 10-Q
34 05-03-2017 03-31-2017 10-Q
35 02-17-2017 12-31-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-03-2016 06-30-2016 10-Q
38 05-04-2016 03-31-2016 10-Q
39 02-19-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bank-earnings-lift-wall-street-gold-hits-4200-whats-moving-markets-wednesday

Wall Street rose on Wednesday, with investor optimism lifted by strong bank and corporate earnings alongside growing expectatio...

 abbott-tightens-annual-sales-forecast-as-q3-sales-miss-expectations

Abbott stock fell as Q3 sales missed estimates and 2025 earnings guidance was narrowed despite solid growth in medical devices.

 stock-market-today-sp-500-nasdaq-futures-rise-bank-of-america-morgan-stanley-abbott-earnings-in-focus-updated

Editor’s note: The future prices of benchmark tracking ETFs, the lede, and the latest economic releases were updated in the sto...

 abbott-laboratories-narrows-fy2025-adj-eps-guidance-from-510-520-to-512-518-vs-515-est

ABBOTT'S FINANCIAL GUIDANCEAbbott reaffirms previously provided full-year 2025 organic sales growth guidance of 7.5% to 8.0...

 dow-jumps-over-200-points-following-strong-bank-earnings-investor-fear-eases-slightly-but-greed-index-remains-in-fear-zone

Dow Jones gains, but trade tensions limit enthusiasm. Wells Fargo, Citi, JPMorgan, and Goldman Sachs beat expectations.

 bank-of-america-morgan-stanley-and-3-stocks-to-watch-heading-into-wednesday

US stock futures higher, BAC, PZZA, MS expected to report earnings, ASML reports better-than-expected bookings, ABT to report e...

 retail-investors-top-stocks-with-earnings-this-week-fastenal-asml-tsmc-and-more

Retail investors are preparing for the kick-off of the Q3 earnings season, with big banks and other top stocks reporting this w...

 benchmark-initiates-coverage-on-abbott-laboratories-with-buy-rating-announces-price-target-of-145

Benchmark analyst Bruce Jackson initiates coverage on Abbott Laboratories (NYSE:ABT) with a Buy rating and announces Price T...

 evercore-isi-group-maintains-outperform-on-abbott-laboratories-raises-price-target-to-144

Evercore ISI Group analyst Vijay Kumar maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price targe...

 the-magnificent-7-boom-just-triggered-a-dot-com-era-warning

The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes.

 short-report-alleges-dexcom-sold-faulty-g7-device-cited-by-fda

Dexcom faces mounting scrutiny over G7 safety concerns, FDA violations, financial practices, and growing competition from Abbot...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION